Objective: To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS).
Methods: Twenty-seven overweight women with PCOS and hypothyroidism were selected. Fifteen patients (group I) were treated with metformin 1500 mg/day for 6 months and 12 patients (group II) with placebo. Serum thyrotropin (TSH), free T3 and free T4 were measured at baseline and 6 months after the beginning of the study.
Results: A significant decrease (p<0.001) in TSH levels was observed in group I but not in group II subjects after 6 months of metformin treatment. No significant change in free T3 and free T4 was observed throughout the study in any group.
Conclusion: In obese PCOS patients with primary hypothyroidism, metformin results in a significant fall and sometimes normalisation of TSH, without causing any reciprocal changes in other thyroid function parameters.
Janssen OE, Mehlmauer N., Hahn S. et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol2004; 150: 363-369.
2.
Cappelli C., Rotondi M., Pirola I. et al. TSH-lowering effect of metformin in type 2 diabetes. Diabetes Care2009; 32: 1589-1590.
3.
Díez JJ, Iglesias P.Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab2004; 89: 4890-7.
4.
Vigersky RA, Filmore-Nassar A. and Glass ARThyrotropin suppression by metformin. J Clin Endocrinol Metab2006; 91: 225-227
5.
Quigley ME, Rakoff JS and Yen SSC.Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab1981 ; 52: 231-234.
6.
Ortega-González C., Cardoza L., Coutiño B. et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol2005; 184: 233-239.
